Pharma giant’s share price has fallen below pre-pandemic levels after shortlived bump from Covid vaccine
Company’s chief oncology officer says reforms risk discouraging treatments for paediatric and rare conditions
Jab makers fall behind Moderna in post-pandemic market with disappointing results
Pharma groups could see almost threefold drop in demand due to US health official decision, says Airfinity
Pharma group seeks to catch up with rivals Eli Lilly and Novo Nordisk in sector projected to be worth $130bn a year
Pfizer and BioNTech infringed pharmaceutical group’s mRNA patent, High Court in London rules
Decision is a boon for the mRNA-vaccine maker in its legal fight to recoup pandemic profits from rivals
Agreement aims to resolve a big portion of litigation in Delaware over discontinued heartburn drug
Drugmaker follows Eli Lilly in cutting out middlemen and selling directly to patients
US pharma group follows Eli Lilly with website for patients to obtain medication online
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
People who progress with little regard for colleagues are likely to hit a ceiling
Millions of Paxlovid pills have gone unused as tight controls restrict access
Company would have been better off following Roche’s route to market for anti-obesity treatment
US drugmaker is trying to chart its future without blockbuster Covid-19 products
Case studies in best practice among general counsel and company legal teams in North America
Decision is setback for US drugmaker looking to increase sales after pandemic
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments
Companies have yet to provide investors with convincing post-pandemic strategies
Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US
BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances
Massachusetts police chief and former pharmaceutical executive also among those indicted by federal prosecutors
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
